Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€212.50

€212.50

-13.970%
-34.5
-13.970%
€310.00

€310.00

 
19:27 / Tradegate WKN: 716560 / Symbol: SARTF / Name: Sartorius / Stock / Healthcare Equipment & Supplies / Mid Cap /
Latest predictions
€320.00
22.03.24
-25.57%
buy
08.02.24
-22.89%
buy
€300.00
18.07.23
-17.41%
buy
12.06.23
-21.91%
buy
Your prediction

Sartorius AG ST Stock

Sartorius AG ST took a tumble today and lost -€34.500 (-13.970%).
Our community is currently high on Sartorius AG ST with 4 Buy predictions and 0 Sell predictions.
As a result the target price of 310 € shows a positive potential of 45.88% compared to the current price of 212.5 € for Sartorius AG ST.
For the coming years our community has positive and negative things to say abot the Sartorius AG ST stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.

Sartorius is a German-based biotech and laboratory equipment company that is listed on the Frankfurt Stock Exchange under the symbol SARTF. The company provides products and services for the pharmaceutical, biotech, and food industries, including laboratory instruments, consumables, and services. Sartorius has a global presence with operations in Europe, Asia, and the Americas, and has a strong reputation for innovation, quality, and reliability. The company's stock has performed well in recent years, reflecting its solid financial results and growth prospects in the life sciences industry.

Pros and Cons of Sartorius AG ST in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Sartorius AG ST vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Sartorius AG ST -13.970% -6.616% -11.311% -22.933% -6.439% -40.838% 78.986%
Sartorius AG VZO -15.930% -2.946% -9.751% -16.158% -0.693% -30.161% 117.635%
Healthequity Inc. - 4.167% 0.000% 44.231% 26.050% 28.733% -
Integer Hldg -1.790% 4.673% 7.692% 56.643% 25.843% 44.516% 72.281%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-20

Sartorius is an established player in the Healthcare Equipment & Supplies industry, and their financials reflect a strong position in the market. The company has displayed consistent growth in revenues, assets, and shareholder equity over the years. However, there are certain aspects of their financials that may warrant closer scrutiny.

Increasing Revenue: Sartorius has experienced consistent growth in its total revenue over the past three years, increasing from €2,335,657,000 in 2020 to €4,174,700,000 in 2022.

Growth in Total Assets: The company has reported a substantial increase in its total assets, which rose from €4,697,348,000 in 2020 to €6,977,700,000 in 2022. This demonstrates a strong financial position and the potential for further growth.

Comments

systinvest bought the security Sartorius AG in his wikifolio Aktienwertselektion mit System.
Show more

News

EQS-News: Sartorius: First quarter results in line with expectations; recurring business with significant order growth; demand from China remains weak; outlook for full year confirmed: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-News: Sartorius: First quarter results in line with expectations; recurring business with significant order growth; demand from China remains weak; outlook for full year confirmed
EQS-News: Sartorius: First quarter results in line with expectations; recurring business with significant order growth; demand from China remains weak; outlook for full year confirmed
EQS-News: Resolutions of the Annual General Meeting of Sartorius AG: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-News: Resolutions of the Annual General Meeting of Sartorius AG
EQS-News: Resolutions of the Annual General Meeting of Sartorius AG
EQS-News: Sartorius releases Annual Report for 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-News: Sartorius releases Annual Report for 2023
EQS-News: Sartorius releases Annual Report for 2023